Shenzhen Hepalink Pharmaceutical Group logo

Shenzhen Hepalink Pharmaceutical Group(SEHK) 9989

Market CapHK$5.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-74%
5 Year-56%
1 Year-27%
1 Month-6%
HK$3.93
+0.51%
+0.02Today
Shenzhen Hepalink Pharmaceutical Group last closing stock price
MetricPriceDate
Last closeHKD 3.922026-10-15
Shenzhen Hepalink Pharmaceutical Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.82%HKD 3.852026-10-08
1 month-5.77%HKD 4.162026-09-15
3 month-6.89%HKD 4.212026-07-17
Year to date-24.76%HKD 5.212025-12-31
1 year-27.41%HKD 5.402025-10-15
3 year-2.73%HKD 4.032023-10-16
5 year-55.56%HKD 8.822021-10-15
Since inception-74.44%HKD 15.282020-07-08

Shenzhen Hepalink Pharmaceutical Group Financials at a Glance

Market Cap

HK$5.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥5.24B

Net Income (TTM)

CN¥202.88M

EPS (TTM)

HK$0.16

P/E Ratio

24.62

Dividend

HK$0.17

Beta (Volatility)

0.02 (Low)

Price

HK$3.93

Volume

805,500

Open

HK$3.93

Previous Close

HK$3.91

Daily Range

HK$3.90 - HK$4.00

52-Week Range

HK$3.74 - HK$5.77

Estimated Earnings Date

Nov 4, 2026

9989 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shenzhen Hepalink Pharmaceutical Group

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is an international pharmaceutical company based in Shenzhen, China. Established in 1998, the company specializes in the development, production, and distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients and finished dose products.

Products and Services
  • Finished Dose Pharmaceutical Products, including enoxaparin sodium injection
  • Active Pharmaceutical Ingredients (API) such as heparin sodium and enoxaparin sodium
  • Contract Development and Manufacturing Organization (CDMO) services for biopharmaceuticals
Growth Outlook
  • Revenue of CNY 1.25 billion in Q2 2026, showing strong market demand
  • Net income of CNY 87.7 million in Q2 2026, indicating profitability
  • Consistent investment in R&D, with CNY 45.9 million spent in Q2 2026
Financial Highlights
  • Trailing twelve-month revenue of CNY 5.4 billion, reflecting robust sales growth
  • Operating income margin of 5.83% in Q2 2026, showcasing operational efficiency
  • Dividend yield of 1.49% TTM, providing a return to shareholders
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. operates across multiple segments, focusing on both finished pharmaceutical products and active ingredients. The company has demonstrated a strong growth trajectory, with recent quarterly results indicating a solid revenue stream and profitability. The commitment to research and development is evident, as significant resources are allocated to innovate and enhance product offerings. Financially, the company maintains a healthy operating margin and offers dividends, which may appeal to investors seeking both growth and income. Overall, Shenzhen Hepalink presents a compelling opportunity in the pharmaceutical sector, backed by a strong operational foundation and a clear growth strategy.
AI Generated • Oct 12, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,150

CEO

Yu Shan

Website

www.hepalink.com

Headquarters

Shenzhen, GD 518057, CN

9989 Financials

Key Financial Metrics (TTM)

Gross Margin

33.81%

Operating Margin

9.22%

Net Income Margin

3.87%

Return on Equity

1.67%

Return on Capital

4.50%

Return on Assets

1.23%

Earnings Yield

4.06%

Dividend Yield

4.25%

Payout Ratio

1.22%

Stock Overview

Market Cap

HK$5.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.47B

Volume

805.50K

Avg. Volume

575.31K

Financials (TTM)

Gross Profit

CN¥1.75B

Operating Income

CN¥191.61M

EBITDA

CN¥549.59M

Operating Cash Flow

CN¥1.50B

Capital Expenditure

-CN¥80.86M

Free Cash Flow

CN¥1.42B

Cash & ST Invst.

CN¥3.55B

Total Debt

CN¥2.89B

Shenzhen Hepalink Pharmaceutical Group Performance Analysis

Shenzhen Hepalink Pharmaceutical Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 8,321,672,7458.5%
20232023-12-31CNY 6,016,273,510-27.7%
20242024-12-31CNY 5,721,399,746-4.9%
20252025-12-31CNY 5,916,535,4073.4%
Shenzhen Hepalink Pharmaceutical Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-3.2%
Q42025-12-31-6.7%
Q12026-03-313.6%
Q22026-06-30-6.2%
Shenzhen Hepalink Pharmaceutical Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.58191.5%
20232023-12-31CNY -0.59N/A
20242024-12-31CNY 0.48N/A
20252025-12-31CNY 0.26-46.0%
Shenzhen Hepalink Pharmaceutical Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-50.1%
Q42025-12-31-255.9%
Q12026-03-31192.9%
Q22026-06-30-54.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥1.25B

-12.3%

Gross Profit

CN¥427.59M

-13.9%

Gross Margin

34.24%

N/A

Market Cap

HK$5.73BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$2.67M

N/A

Employees

2,150

N/A

Net Income

CN¥87.71M

-66.9%

EBITDA

CN¥219.81M

-47.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥3.55B

+15.9%

Total Debt

CN¥2.89B

+22.1%

Accounts Receivable

CN¥1.64B

+9.6%

Inventory

CN¥3.92B

-16.0%

Long Term Debt

CN¥59.75M

-89.5%

Short Term Debt

CN¥2.84B

+57.4%

Return on Assets

1.23%

N/A

Return on Invested Capital

3.86%

N/A

Free Cash Flow

CN¥419.62M

-9.7%

Operating Cash Flow

CN¥437.79M

-13.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,709.28-0.01%
^DJIDJI
$51,466.30-0.00%
^IXICNASDAQ
$26,684.28-0.02%
BTCBitcoin
$81,564.00-0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$42.52+13.63%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.12-5.95%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$36.00+5.93%

Questions About 9989

What is the current price of Shenzhen Hepalink Pharmaceutical Group?

Shenzhen Hepalink Pharmaceutical Group is trading at HK$3.93 per share.

What is the 52-week range for Shenzhen Hepalink Pharmaceutical Group?

Over the past 52 weeks, Shenzhen Hepalink Pharmaceutical Group has traded between HK$3.74 and HK$5.77.

How much debt does Shenzhen Hepalink Pharmaceutical Group have?

As of the most recent reporting period, Shenzhen Hepalink Pharmaceutical Group reported total debt of CN¥3.38B.

How much cash does Shenzhen Hepalink Pharmaceutical Group have on hand?

Shenzhen Hepalink Pharmaceutical Group reported CN¥1.76B in cash and cash equivalents in its most recent financial results.

What is Shenzhen Hepalink Pharmaceutical Group’s dividend yield?

Shenzhen Hepalink Pharmaceutical Group currently has a dividend yield of 4.25%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services